The doctor diagnosed his illness as
diabetes.
医生诊断他的病是糖尿病。
My grandfather has
diabetes,he has to inject drug before dining every day.
他的外祖父患有糖尿病，他不得不每天在吃饭前注射胰岛素
According to the agreement, the company will spend 190 million yuan ($26.5 million) to build a new production line for Dapagliflozin and Metformin Hydrochloride, a diabetes therapy that was marketed in China last November.
根据协议，该公司将斥资1.9亿元人民币（2650万美元）建造一条新的达格列嗪和盐酸二甲双胍生产线，后者是一种糖尿病疗法，去年11月在中国上市。
AstraZeneca said it plans to turn the Taizhou base into a global production and supply base for the company's diabetes products.
阿斯利康表示，计划将泰州基地打造成该公司糖尿病产品的全球生产和供应基地。
The investment agreement aims to introduce core technologies of diabetes drugs and related production and supply chains to build Taizhou into a global production base of AstraZeneca in relation to diabetes.
该投资协议旨在引入糖尿病药物及相关生产和供应链的核心技术，将泰州打造成阿斯利康糖尿病全球生产基地。
AstraZeneca has been developing in China for 30 years, constantly increasing investment and building an efficient supply network, Lin said, noting that last year, AstraZeneca added a new production line in Taizhou, East China's Jiangsu province, with an expected annual output value of over 10 billion yuan ($1.37 billion), which will help turn the city into a global manufacturing base for AstraZeneca's diabetes products.
林说，阿斯利康在中国发展了30年，不断增加投资，建立了高效的供应网络。他指出，去年，阿斯利康在中国东部江苏省泰州市增加了一条新的生产线，预计年产值将超过100亿元人民币（13.7亿美元），这将有助于将该市转变为阿斯利康糖尿病产品的全球制造基地。
The company's exhibits this year will include several intelligent and personalized products that address people's growing concerns about diabetes care and cardiovascular healthcare.
该公司今年的展品将包括几种智能和个性化的产品，以解决人们对糖尿病护理和心血管保健日益增长的担忧。
Basil mentioned that the company recently has two blockbuster products - a medicine to treat obesity in some international markets and diabetes in some others as well as another potential drug achieving good results in Alzheimer's disease researches.
巴西尔提到，该公司最近推出了两款重磅产品——一种在一些国际市场治疗肥胖的药物，另一种在阿尔茨海默病研究中取得良好效果的潜在药物。
Regarding diabetes, roughly one in four people in the world with the disease are in China, and only about half of them are in control of their disease situations.
关于糖尿病，世界上大约四分之一的糖尿病患者在中国，其中只有大约一半的人能够控制自己的病情。
Besides, several of its innovative products in the areas of autoimmune, cardiovascular and kidney diseases as well as diabetes have been included in the latest version of the National Reimbursement Drug List.
此外，其在自身免疫、心血管和肾脏疾病以及糖尿病领域的一些创新产品已被列入最新版本的国家报销药物清单。
Following its official market release of an innovative drug into the Chinese mainland market for the treatment of adults with insufficiently controlled type 2 diabetes mellitus, the company plans to invest hundreds of millions of yuan in the Beijing manufacturing site, Shi said.
施说，在一种用于治疗2型糖尿病患者的创新药物正式进入中国大陆市场后，该公司计划在北京的生产基地投资数亿元。
Type 2 diabetes is a chronic disease in which a patient's pancreas does not make enough insulin, resulting in high blood sugar levels.
2型糖尿病是一种慢性疾病，患者的胰腺不能产生足够的胰岛素，导致血糖水平升高。
"We expect to introduce more than 25 innovative products into China between 2020 and 2025, covering immunity and inflammation, rare diseases and rare blood diseases, oncology, vaccines, cardiovascular and diabetes," Shi added.
施补充道：“我们预计在2020年至2025年期间将向中国引进超过25种创新产品，涵盖免疫和炎症、罕见病和罕见血液病、肿瘤学、疫苗、心血管和糖尿病。”。
The company established a global clinical data operations center in Chengdu, Sichuan province as early as 2018, and in 2021, it opened the Sanofi Institute for Biomedical Research in Suzhou, Jiangsu province — its first global research institute in China that focuses on cutting-edge biological research in major disease areas such as immunization and inflammation, oncology, rare diseases or rare blood disorders, neurology and diabetes.
该公司早在2018年就在四川省成都市建立了全球临床数据运营中心，并于2021年在江苏省苏州市开设了赛诺菲生物医学研究所，这是其在中国的第一家全球研究机构，专注于免疫与炎症、肿瘤学、，罕见病或罕见血液疾病、神经病学和糖尿病。
The technologies include those in the fields of diagnostics, cardiovascular care, nutrition, diabetes care and established pharmaceuticals businesses.
这些技术包括诊断、心血管护理、营养、糖尿病护理和已建立的制药企业领域的技术。
According to the agreement, Abbott will donate 3,000 sets of its fingerstick-free glucose monitoring system FreeStyle Libre and provide professional services to the foundation to better support children with Type 1 diabetes and pregnant women with gestational diabetes.
根据协议，雅培将捐赠3000套无手指血糖监测系统FreeStyle Libre，并为基金会提供专业服务，更好地支持1型糖尿病儿童和妊娠期糖尿病孕妇。
The FreeStyle Libre portfolio provides diabetes patients with real-time readings, trends, and historical records of their glucose levels.
FreeStyle Libre产品组合为糖尿病患者提供血糖水平的实时读数、趋势和历史记录。
Abbott had on Jan 29 announced that its application to expand the use of FreeStyle Libre to children aged 4 and above with diabetes was approved.
雅培于1月29日宣布，其将FreeStyle Libre的使用范围扩大到4岁及以上糖尿病儿童的申请已获批准。
The morbidity rate of Type 1 diabetes has been rising in China over the last few years.
近几年来，中国1型糖尿病的发病率一直在上升。
China is currently ranked fourth in the world in terms of the number of children aged 14 or younger suffering from Type 1 diabetes.
就14岁及以下儿童患1型糖尿病的人数而言，中国目前位居世界第四。
More than 90 percent of children with diabetes are classified as Type 1.
90%以上的糖尿病儿童属于1型糖尿病。
As patients with Type 1 diabetes need lifelong insulin treatment, scientific and efficient glucose management is important, according to medical experts.
医学专家表示，由于1型糖尿病患者需要终身胰岛素治疗，科学有效的血糖管理很重要。
The care for children and pregnant women demonstrates Abbott's commitment to contributing to intelligent and efficient diabetes management in China," said Jerry Guo, general manager of diabetes care of Abbott in Greater China.
雅培大中华区糖尿病护理总经理Jerry Guo表示：“对儿童和孕妇的护理表明，雅培致力于为中国智能高效的糖尿病管理做出贡献。
In 2020, Bayer and Hua Medicine announced their commercialization agreement and strategic partnership for dorzagliatin, which was approved in September 2022 as the first GK activator in China for treating diabetes under the brand name of HuaTangNing.
2020年，拜耳和华医药宣布了多扎利汀的商业化协议和战略合作伙伴关系，该药物于2022年9月以华汤宁品牌获批为中国首个治疗糖尿病的GK激活剂。
Since Abbott's first participation at the second CIIE, many of its healthcare solutions, such as the total laboratory automation solution and its FreeStyle Libre series that offer more personalized and intelligent diabetes management, have become more accessible in China thanks to the spillover effect of the CIIE, the company said.
雅培表示，自雅培首次参加第二届中国国际糖尿病联合会以来，由于中国国际糖尿病联会的溢出效应，雅培的许多医疗保健解决方案，如全实验室自动化解决方案和提供更个性化和智能化糖尿病管理的FreeStyle Libre系列，在中国变得更容易获得。
In addition, the market launch of Kerendia™ for the treatment of patients with chronic kidney disease and type 2 diabetes during the third quarter of 2021 had a positive impact.
此外，2021年第三季度，用于治疗慢性肾脏疾病和2型糖尿病患者的Kerendia™的市场推出产生了积极影响。
These patients include the elderly and people with chronic kidney or lung issues, cardiovascular disease, diabetes and other high-risk factors.
这些患者包括老年人和患有慢性肾脏或肺部问题、心血管疾病、糖尿病和其他高危因素的人。
In September, 2020, Sanofi, together with JD Health, a digital healthcare platform under JD, launched an online center for the diagnosis and treatment of diabetes, the first health management platform for Chinese patients with diabetes, which ushers in a new era of one-stop health management service.
2020年9月，赛诺菲联合京东旗下数字健康平台京东健康，推出了中国首个糖尿病患者健康管理平台——糖尿病在线诊疗中心，开启了一站式健康管理服务的新时代。
Parents of young diabetes patients mainly bought the devices," said Masayuki Maruta, president and CEO of Terumo (China) Holdings Co Ltd. "Afterward, more enterprises contacted us, inquiring about the device and seeking collaboration opportunities.
Titled "Inventing for Life, for a Healthier China", a suite of exhibits highlight MSD's four-pronged areas of focus in the country: oncology, vaccines, diabetes and anti-infectives, along with animal health products.
Sanofi is scheduled to introduce at least 25 new products into the China market by 2025, covering therapies in areas such as immunology, rare diseases, oncology, rare blood disorders, neurology, cardiovascular disease and diabetes, as well as vaccines.
The app can not only help diabetes patients monitor their real-time glucose levels but also share the data with their families and medical professionals through cloud technology.
According to Bayer, during this year's CIFTIS, it will demonstrate its innovative drugs in diabetes, cardiovascular diseases and cancer.
US-based Abbott, a global leading healthcare company, collaborated with the Beijing Medical Award Foundation to launch a demonstrative glucose monitoring program, in an effort to promote higher-quality and more intelligent diabetes management in China.
Mu Yiming, professor at the First Medical Center of the Chinese People's Liberation Army General Hospital, said: "Continuous glucose monitoring lays a solid foundation for intelligent diabetes management.
Abbott's innovative technology enables patients to manage their conditions more accurately and lower the risk of complications, helping to improve diabetes management.
"Diabetes is a major challenge for China's public health.
According to the 2020 China Guideline for Type 2 Diabetes launched by the Chinese Diabetes Society, currently, China has become the country with the largest diabetic population, and the morbidity among people aged above 18 was 11.2 percent.
China's average annual spending on diabetes reached 621 billion yuan ($95.9 billion), and that of complications associated with diabetes was nearly 593 billion yuan.
Jerry Guo, general manager of Diabetes Care at Abbott China, said: "The program will enable Abbott to work with BMAF and major hospitals in China to standardize continuous glucose monitoring.
""Our world-leading FreeStyle Libre technology provides both individuals and hospitals with technology to manage diabetes accurately and intelligently that ultimately leads to better health outcomes.
We will continue to optimize the FreeStyle Libre ecosystem to create a more comprehensive diabetes management solution to address the unmet needs of Chinese patients," he said.
Currently, its FreeStyle Libre system has entered hospitals in large and medium-sized cities in 28 provinces, covering tens of thousands of diabetes patients.
In the future, the company will continue to make technological innovations, to bring scientific and effective disease management solutions to more diabetes patients, satisfying their needs while promoting China's development in diabetes prevention, diagnosis and management, Abbott said.
"Novo Nordisk, a global leader in diabetes care, will continue to invest in a sustainable and innovation-based healthcare ecosystem in China, he said.
As China enters a new development phase featuring the dual-circulation development paradigm, which takes the domestic market as the mainstay while letting domestic and foreign markets reinforce each other, there will be significant opportunities for the company to continue enhancing its presence across the whole value chain and strengthen innovation and production capabilities to fulfill the growing needs of people with diabetes in China and globally, said Jorgensen.
Common misconceptions brought up by patients include that surgery must not be done until cataracts are fully developed, that medication can cure cataracts and that patients with diabetes, high blood pressure, cardiovascular diseases, glaucoma or other diseases cannot undergo surgery.
With this strategic partnership, Servier China will leverage on Yixintang's broad network, strong marketing capabilities, flexible and diversified channels and innovative services that integrate online and offline, to provide innovative services such as marketing, retail coverage, internet hospital projects and supply chain services for its complete product portfolio, including drugs for treatment of the diabetes, hypertension and cardiovascular disease.
As one of the first multinational companies that entered China more than 40 years ago, Servier has been an industry leader in cardiovascular disease and diabetes.
"With the help of the measures to deepen China's reform and opening-up such as the hosting of CIIE, the company will leverage this opportunity to further root itself in the China market and work toward its commitment to changing the situations of diabetes and other chronic diseases in the country," Zhou said.
China's health service provider Health 100 launched a program in Beijing on Friday to promote diabetes prevention and control awareness, as a follow-up event to its long-term commitment to the cause.
The company will join hands with Shanghai Soong Ching Ling Foundation to unveil the nationwide sugar control charity program in Hebei and Liaoning provinces, and Inner Mongolia, where diabetes incidence rates are high, to conduct diabetes screening, public education, and post-inspection management services.
According to the International Diabetes Federation, about 463 million adults aged 20 to 79 were suffering from diabetes in the world in 2019.
China had about 116.4 million diabetes patients, ranking first in the world.
Diabetes has become a major public health problem that seriously endangers the health of Chinese people and brings a heavy economic burden to social medical care, as it is estimated China has spent $109 billion on diabetes-related health expenditures.
Guo Lixin, board director-elect of Chinese Diabetes Society, said to prevent and control diabetes it is important to reduce the risk of diabetes in high-risk groups, while for diagnosed patients, blood sugar control should be strengthened to reduce the risk of complications.
In addition to diabetes, drugs to introduce will cover more disease areas, including obesity, hemophilia, and other chronic diseases.
At the same time, they will expand their diabetes and hemophilia research funds, and continue to create a high-end international academic communication platform through the Novo Nordisk's Young Scientific Talent Development Program.
These projects focus on diabetes, obesity and other chronic diseases, and explore new technologies, such as AI-assisted research.
We are helping to build China's pharmaceutical innovation ecosystem so we can further explore and develop innovative drugs for diabetes and other serious chronic diseases.
"China is one of Novo Nordisk's most important markets, and we will continue to develop in China to serve more Chinese people with diabetes, and through China Essentials 2.0, help bring Chinese innovation to the world. "
Between January 2018 and September 2020, the company secured 25 medicine approvals in China in some disease areas with great patient need, including immunology, mental health, oncology, diabetes, infectious diseases, and rare diseases.
Cardiovascular diseases and diabetes remain among major chronic diseases which are prioritized by the Chinese central government in its Healthy China Action Plan in efforts to address major health challenges caused by the prevalence of chronic diseases.
Bayer and Hua Medicine, a leading innovative drug development company, announced a commercial agreement and strategic partnership for dorzagliatin, a novel diabetes treatment, in China on Monday.
The agreement aims to give Chinese diabetes patients access to a new treatment option, building on Bayer's existing strength and leadership in diabetes management in China and the innovation capabilities of Hua Medicine.
"Bayer has been long committed to Chinese patients living with diabetes and diabetic macular edema (DME) by offering innovative treatment options, including Glucobay and Eylea," said Wei Jiang, executive vice-president and president of Bayer Pharmaceuticals Region China & APAC, and president of Bayer Group Greater China.
"In the face of significantly increasing challenges caused by diabetes to public health in China, our collaboration with Hua Medicine will further address the unmet medical needs of Chinese patients living with diabetes.
""We are very excited to have this great opportunity, joining forces with Bayer to bring a first-in-class diabetes medicine, dorzagliatin, to Chinese patients," said Li Chen, CEO of Hua Medicine.
"Bayer has been a leader in diabetes treatment for the past 10 years in China and will be a great partner for Hua Medicine to advance diabetes care.
The company's devices equipped with chronic management system proved to be of immense help to the medical professionals in Wuhan, especially while treating COVID-19 patients with diseases such as diabetes.
The collaboration aims to provide innovative glucose monitoring solutions to patients and physicians in China by integrating WaveForm's novel and proprietary technologies with Bayer's extensive experience and know-how in diabetes management.
Regular glucose monitoring plays a vital role in improving diabetes management outcomes.
According to the 2017 Chinese Clinical Guideline for CGM, continuous glucose monitoring can track glucose levels continuously and comprehensively, indicating daily glycemic fluctuations in individuals, which serves as a valuable measurement for assessing and guiding treatment of diabetes.
"Bayer is committed to providing solutions in diabetes management in China through its expertise and a portfolio of well-established brands," said Wei Jiang, executive vice-president and president of Bayer Pharmaceuticals Region China & APAC and president of Bayer Group Greater China.
"The partnership with WaveForm will extend our efforts across overall diabetes management (ranging from glucose monitoring, prevention and treatment of diabetes to tackling complications); better addressing the unmet medical needs of Chinese patients and thereby helping to improve their quality of life," he said.
According to the latest figures published by International Diabetes Federation, an estimated 116 million adults in China are living with diabetes, and over 65 million of these are undiagnosed.
A study published in the Journal of American Medical Association showed that among people with diabetes in China, 32.2 percent were treated and 49.2 percent of patients treated had adequate glycemic control.
To address the growing challenges caused by the prevalence of diabetes in China, Bayer has been actively collaborating with industry associations, healthcare professionals and other partners to advance diabetes management through integrated approaches including public education, screening, prevention and treatment.
For example, since 2019, Bayer has been working with the China Health Promotion Foundation on the Diabetes Prevention project.
This initiative leverages both an online interactive platform and on-site programs such as expert consultation and community education activities to raise public awareness and health literacy on diabetes prevention and treatment, thus helping to improve outcome of diabetes management.
"Leveraging the expertise and leadership that Bayer has established in diabetes management, it will deliver more benefits for patients in China.
As a wholly owned subsidiary of AgaMatrix Holdings LLC, WaveForm discovers and develops novel and proprietary new technologies for diabetes care.
WaveForm is also developing a proprietary "closed loop" insulin delivery platform designed to provide a complete solution for patients living with diabetes.
The China Essentials program not only focuses on chronic diseases such as diabetes and obesity, but aims to help patients in new therapeutic areas such as haemophilia, growth disorders and nonalcoholic steatohepatitis, said Zhang Kezhou, corporate vice president of Novo Nordisk China.
At present, the once-weekly semaglutide injection (Ozempic) which is being used to treat people with diabetes overseas, has been submitted for new drug approval in China for treatment of diabetes, and we have been approved to initiate clinical trials for obesity treatment with semaglutide injections in China, which is not yet on global markets.
Qingdao Baheal Pharmaceutical Co Ltd, a holding subsidiary of Chinese pharmaceutical giant Baheal Pharmaceutical Group, announced on Tuesday that its high-end generic medicine, "Nida", an extended-release tablet containing metformin for type-2 diabetes management, was officially launched in China.
According to the International Diabetes Federation, China currently has more than 116.4 million diabetic patients, and most of them suffer from type-2 diabetes.
Abbott also has special medical nutrition products for patients with diabetes.
Most of the additions are new drugs of high clinical value that can be used to treat multiple diseases including cancer, diabetes and tuberculosis, and the prices of most imported drugs will be set at the lowest in the world, said Xiong Xianjun, a senior official with the NHSA.
The report said that patients suffering from chronic diseases such as cardiovascular disease and diabetes are mainly from such areas, which shows the need for greater drug accessibility.
In addition, Abbott has special products for patients with diabetes.
Thanks to the continued optimization of the local business environment and the opportunities generated during the deepening of the healthcare reform, Novo Nordisk has made significant progress over the past year in China, and aims to change diabetes for "Healthy China" through showcasing its innovative medicine products at the second China International Import Expo, a senior executive of the Denmark biopharmaceutical company said on Wednesday.
Its INNOVO open innovation platform, digital chronic disease management solution and the "Cities Changing Diabetes" program are all showcased at the CIIE as new attempts over the past few years to expand its industry model and join forces with all parties to address the challenges of diabetes and other metabolic diseases.
Novo Nordisk has also shared its impressive array of achievements from its 25 years' presence in China, including a full range of high-quality therapeutic product portfolio, substantial R&D pipeline, leading-edge global research findings, global digital health care solutions, and the remarkable accomplishments of the Cities Changing Diabetes.
"Novo Nordisk will continue to drive the cause of Changing Diabetes in China and support its Healthy China 2030 vision through innovation and cooperation. "
Novartis also signed a collaboration agreement with the Eye Hospital affiliated with Shandong University of Traditional Chinese Medicine and Shandong Provincial Light Charity Foundation to focus on the eye health of diabetes patients in the province.
The three sides will cooperate to set up an alliance of hospitals to standardize the diagnosis and treatment of eye health problems among diabetes sufferers, and promote early screening and checkups at local community health centers.
The number of diabetes patients is estimated at 8.7 million in Shandong province, and roughly 2 million are thought to suffer from diabetic retinopathy, according to Bi Hongsheng, a national legislator and director of the Eye Hospital affiliated with Shandong University of TCM.
"Through this cooperation, we hope to gather advantages and resources from the (involved) parties to standardize the eye health treatment available to diabetes patients, and to prevent blindness for such patients through early prevention and screening," he said.
The new mutual aid program will cover nearly 60 kinds of illnesses, such as stroke and diabetes.
In addition to preventing and dealing with gastric cancer, liver cancer and diabetes, people in China should avoid excessive use of antibiotics as it could affect health, she said.
The program will focus on innovative treatments for diabetes and other chronic conditions the company specializes in, such as obesity, cardiovascular and chronic kidney diseases.